| Protocol | Title | Coordinating Group |
| 06071 | A phase III randomized, Double-blind study of induction (Daunorubicin/Cytarabine) and consolidation (high-dose Cytarabine) chemotherapy + Midostaurin (PKC 412) (IND # TBD) or Placebo in newly diagnosed patients <60 years of age with FLT3 mutated acute myeloid leukemia (AML) | Cancer and Leukemia Group B |
| 08072 | Concurrent once-daily versus twice-daily radiotherapy : A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status (CONVERT). | Christie's Hospital |
| 10031 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer tamoxifen versus ovarian function suppression + tamoxifen versus ovarian function suppression + exemestane (SOFT). | International Breast Cancer Study Group |
| 10071 | A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer | Breast European Adjuvant Studies Team |
| 22051 | Selective Use of Postoperative Radiotherapy AftEr MastectOmy (SUPREMO) | Scottish Cancer Trials Breast Group |
| 22085 | A randomized phase III study of radiation doses and fractionation schedules for ductal carcinoma in situ (DCIS) of the breast. | Trans-Tasman Radiation Oncology Group Inc |
| 26062 | A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients | National Cancer Institute of Canada-Clinical Trial Group |
| 30072 | A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse | Medical Research Council |
| 58051 | International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia | Operating Center for Research and Statistics |